ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Atropos Health and Emory Healthcare Collaborate on Rapid Generation of Real-World Evidence to Advance Patient Care Through Medication Solutions

Atropos Health, a pioneer in translating clinical data into personalized real-world evidence (RWE) and insights, announced its selection by Emory Healthcare, an academic health system in Georgia, to generate evidence from real-world data (RWD) through a new decision-making tool for clinicians. The tool aims to improve patient outcomes and lower costs through medication solutions.

This collaboration enables Atropos Health to provide rapid evidence generation, advanced analytics, and studies to advance patient care. In the pilot program, Emory is utilizing Atropos Health’s evidence generation platform to answer clinical questions in real-time. By accessing large, historically untapped, local clinical data, Emory and Atropos hope to make impactful changes to medication formulary design and protocols, directly impacting the quality of patient care.

The Atropos EvidenceTM Network, with over 300M patient records, is working with Emory users to run studies on both large national datasets and local Emory data. Clinicians can use the Green ButtonTM for seamless access to real-world evidence, generating results through supervised evidence development or fully automated generative AI version (ChatRWD®) for observation studies delivered in minutes.

"Achieving the quadruple aim in healthcare requires closing the evidence gap,” said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. "Emory’s commitment to adopting technology to reduce friction for physicians and make care protocol and formulary designs based on evidence puts them ahead."

“Atropos Health provides a means to answer questions not specifically or robustly answered in published data; Atropos surfaces practice-based evidence where evidence-based medicine does not exist,” said Alistair Erskine, MD, Enterprise Chief Information and Digital Officer for Emory Healthcare and Emory University. “We are already seeing early success as one of our users explored real-world outcomes, adverse events, and costs of a drug that will improve our drug therapy protocol and benefit Emory patients.”

Customers rely on Atropos Health’s portfolio of evidence-generating solutions through the federated installation of GENEVA OS™ in their internal cloud data environment. GENEVA OS customers can access Alexandria™, a collection of tens of thousands of existing studies, as well as pre-existing content packages including pharmacy, value-based care, and care management. The existing studies in Alexandria can be rerun on local data to generate novel content and evidence for customer use.

About Atropos Health

Atropos Health is the developer of GENEVA OS, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improve individual patient outcomes with data-driven care, expedite research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant, real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com, connect through LinkedIn, or follow on X @AtroposHealth.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.